Authors
Alexander W Wyatt, Arun A Azad, Stanislav V Volik, Matti Annala, Kevin Beja, Brian McConeghy, Anne Haegert, Evan W Warner, Fan Mo, Sonal Brahmbhatt, Robert Shukin, Stephane Le Bihan, Martin E Gleave, Matti Nykter, Colin C Collins, Kim N Chi
Publication date
2016/12/1
Journal
JAMA oncology
Volume
2
Issue
12
Pages
1598-1606
Publisher
American Medical Association
Description
Importance
The molecular landscape underpinning response to the androgen receptor (AR) antagonist enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) is undefined. Consequently, there is an urgent need for practical biomarkers to guide therapy selection and elucidate resistance. Although tissue biopsies are impractical to perform routinely in the majority of patients with mCRPC, the analysis of plasma cell-free DNA (cfDNA) has recently emerged as a minimally invasive method to explore tumor characteristics.
Objective
To reveal genomic characteristics from cfDNA associated with clinical outcomes during enzalutamide treatment.
Design, Setting, and Participants
Plasma samples were obtained from August 4, 2013, to July 31, 2015, at a single academic institution (British Columbia Cancer Agency) from 65 patients with mCRPC. We collected temporal plasma samples (at …
Scholar articles
AW Wyatt, AA Azad, SV Volik, M Annala, K Beja… - JAMA oncology, 2016